에 대한 최신 뉴스 Molina Healthcare (NYSE:MOH) 주식

MOLINA HEALTHCARE INC

Molina Healthcare

Molina Healthcare Inc offers healthcare plans focused on Medicaid-related solutions for low-income families and individuals. Its health plans are operated by a network of subsidiaries, each of which is licensed as a health maintenance organization (HMO). It has four segments: Medicaid, Medicare, Marketplace and Others. The Medicaid, Medicare, and Marketplace segments represent the government-funded or sponsored programs under which it offers managed healthcare services. The Other segment, which is insignificant to its consolidated results of operations, includes long-term services and supports consultative services in Wisconsin. It generates majority revenue from Medicaid segment.

GameStop's Trajectory

Equities

Large Cap

News

Movers

Trading Ideas

CRWV

GOOG

GOOGL

NVDA

ROST

지난주 3월 31일부터 4월 4일까지 S&amp;P 500 지수는 약 9.1% 하락했으며 이는 벤치마크 지수로서 최악의 주간 실적 중 하나로 기록되었다. 하지만 전반적인 시장 매도세 속에서도 상승한 대형주가 있었다. 

코어위브·게임스탑 등 월가 최악의 주간에도 상승한 대형주 10종목 (3월 31일~4월 4일)

Healthcare Workers Sound the Alarm

시그나 그룹(NYSE:CI), 몰리나 헬스케어(NYSE:MOH), 유나이티드헬스 그룹(NYSE:UNH) 같은 주요 의료 서비스 회사들의 주가는 도널드 트럼프 대통령이 헬스케어 산업의 가격 투명성 규제를 강화하기 위한 행정명령에 서명한 이후 수요일(26일) 하락했다.

헬스케어 주식, 트럼프의 가격 투명성 관련 행정명령 서명 이후 하락세

Humana

Analyst Color

Earnings Beats

Guidance

Health Care

Analyst Ratings

General

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

미국의 의료 보험 회사 휴매나(NYSE:HUM)의 주식은 수요일 소폭 상승 마감했다. 화요일 이 회사는 4분기 조정 주당순이익이 2.16달러 손실이라고 발표했다. 이는 전년 대비 11센트 감소한 수치로, 컨센서스와 일치하며 별 등급제에 대한 추가 투자를 포함한 것이다.

휴매나의 2025 전망, 산업 압박에도 불구하고 조심스러운 낙관론을 보여

Molina Healthcare Inc

MOTOR OIL HELLAS CORINTH by Motor Oil (Hellas) Corinth Refineries S.A.

Motor Oil (Hellas) Corinth Refineries SA

MOTOR OIL HELLAS UNSP/ADR by Motor Oil (Hellas) Corinth Refineries S.A.

Collaborative Investment Series Trust Mohr Growth ETF

Mohawk Industries Inc

Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) has outperformed the market over the past 10 years by 6.46% on an annualized basis producing an average annual return of 16.88%. Currently, Molina Healthcare has a market capitalization of $17.49 billion. 
Buying $1000 In MOH: If an investor had bought $1000 of MOH stock 10 years ago, it would be worth $4,893.65 today based on a price of $322.79 for MOH at the time of writing.
<h3>Molina Healthcare's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746463514_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Molina Healthcare Stock In The Last 10 Years

Disclosed on May 1, Richard M Schapiro, Board Member at Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>), executed a substantial insider sell as per the latest SEC filing.
What Happened: A Form 4 filing from the <a href="https://www.sec.gov/Archives/edgar/data/0001179929/000117992925000079//Archives/edgar/data/1179929/000117992925000079/0001179929-25-000079-index.htm">U.S. Securities and Exchange Commission</a> on Thursday showed that Schapiro sold 669 shares of Molina Healthcare. The total transaction amounted to $214,414. 
As of Friday morning, Molina Healthcare shares are down by 0.0%, currently priced at $313.04.
<h3>Get to Know Molina Healthcare Better</h3>
Molina Healthcare Inc offers healthcare plans focused on Medicaid-related solutions for low-income families and individuals. Its health plans are operated by a network of subsidiaries, each of which is licensed as a health maintenance organization (HMO). It has four segments: Medicaid, Medicare, Marketplace and Others. The Medicaid, Medicare, and Marketplace segments represent the government-funded or sponsored programs under which it offers managed healthcare services. The Other segment, which is insignificant to its consolidated results of operations, includes long-term services and supports consultative services in Wisconsin. It generates majority revenue from Medicaid segment.
<h3>Financial Milestones: Molina Healthcare's Journey</h3>
Revenue Growth: Molina Healthcare's remarkable performance in 3 months is evident. As of 31 March, 2025, the company achieved an impressive revenue growth rate of 12.24%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Exploring Profitability:
<ul>
<li>
Gross Margin: With a low gross margin of 11.48%, the company exhibits below-average profitability, signaling potential struggles in cost efficiency compared to its industry peers.
</li>
<li>
Earnings per Share (EPS): Molina Healthcare's EPS is a standout, portraying a positive bottom-line trend that exceeds the industry average with a current EPS of 5.47.
</li>
</ul>
Debt Management: Molina Healthcare's debt-to-equity ratio is notably higher than the industry average. With a ratio of 0.87, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
Financial Valuation Breakdown:
<ul>
<li>
Price to Earnings (P/E) Ratio: The P/E ratio of 15.12 is lower than the industry average, implying a discounted valuation for Molina Healthcare's stock.
</li>
<li>
Price to Sales (P/S) Ratio: The current P/S ratio of 0.42 is below industry norms, suggesting potential undervaluation and presenting an investment opportunity for those considering sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): The company's EV/EBITDA ratio of 6.01 trails industry averages, indicating a potential disparity in market valuation that could be advantageous for investors.
</li>
</ul>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Unmasking the Significance of Insider Transactions</h3>
Insightful as they may be, insider transactions should be considered alongside a thorough examination of other investment criteria.
From a legal standpoint, the term "insider" pertains to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities as outlined in Section 12 of the Securities Exchange Act of 1934. This encompasses executives in the c-suite and significant hedge funds. These insiders are mandated to inform the public of their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
A company insider's new purchase is a indicator of their positive anticipation for a rise in the stock.
While insider sells may not necessarily reflect a bearish view and can be motivated by various factors.
<h3>A Deep Dive into Insider Transaction Codes</h3>
For <a href="https://www.benzinga.com/money/investing-tools">investors</a>, a primary focus lies on transactions occurring in the open market, as indicated in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001179929">Check Out The Full List Of Molina Healthcare's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Insider Unloading: Richard M Schapiro Sells $214K Worth Of Molina Healthcare Shares

In the latest quarter, 11 analysts provided ratings for Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>), showcasing a mix of bullish and bearish perspectives.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $368.0, a high estimate of $414.00, and a low estimate of $325.00. This upward trend is apparent, with the current average reflecting a 4.43% increase from the previous average price target of $352.40.
<img src="https://www.benzinga.com/files/images/story/2025/1745611239_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Molina Healthcare. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Andrew Mok &#x7C;Barclays &#x7C;Raises &#x7C;Equal-Weight &#x7C; $362.00&#x7C;$339.00 &#x7C; 
&#x7C;Lance Wilkes &#x7C;Bernstein &#x7C;Announces &#x7C;Outperform &#x7C; $414.00&#x7C;- &#x7C; 
&#x7C;Michael Ha &#x7C;Baird &#x7C;Raises &#x7C;Neutral &#x7C; $375.00&#x7C;$331.00 &#x7C; 
&#x7C;David Macdonald &#x7C;Truist Securities &#x7C;Raises &#x7C;Buy &#x7C; $400.00&#x7C;$340.00 &#x7C; 
&#x7C;Ann Hynes &#x7C;Mizuho &#x7C;Raises &#x7C;Outperform &#x7C; $400.00&#x7C;$376.00 &#x7C; 
&#x7C;Stephen Baxter &#x7C;Wells Fargo &#x7C;Raises &#x7C;Overweight &#x7C; $372.00&#x7C;$295.00 &#x7C; 
&#x7C;Ann Hynes &#x7C;Mizuho &#x7C;Lowers &#x7C;Outperform &#x7C; $376.00&#x7C;$382.00 &#x7C; 
&#x7C;David Macdonald &#x7C;Truist Securities &#x7C;Lowers &#x7C;Buy &#x7C; $340.00&#x7C;$370.00 &#x7C; 
&#x7C;Andrew Mok &#x7C;Barclays &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $339.00&#x7C;$372.00 &#x7C; 
&#x7C;Kevin Caliendo &#x7C;UBS &#x7C;Lowers &#x7C;Neutral &#x7C; $325.00&#x7C;$374.00 &#x7C; 
&#x7C;Raj Kumar &#x7C;Stephens &amp; Co. &#x7C;Maintains &#x7C;Equal-Weight &#x7C; $345.00&#x7C;$345.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Molina Healthcare. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Molina Healthcare compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Molina Healthcare's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Molina Healthcare's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/MOH/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Molina Healthcare analyst ratings.</a>
<h2>About Molina Healthcare</h2>
Molina Healthcare Inc offers healthcare plans focused on Medicaid-related solutions for low-income families and individuals. Its health plans are operated by a network of subsidiaries, each of which is licensed as a health maintenance organization (HMO). It has four segments: Medicaid, Medicare, Marketplace and Others. The Medicaid, Medicare, and Marketplace segments represent the government-funded or sponsored programs under which it offers managed healthcare services. The Other segment, which is insignificant to its consolidated results of operations, includes long-term services and supports consultative services in Wisconsin. It generates majority revenue from Medicaid segment.
<h3>Molina Healthcare: Financial Performance Dissected</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Positive Revenue Trend: Examining Molina Healthcare's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 6.17% as of 31 March, 2025, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 2.67%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Molina Healthcare's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 6.77% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.86%, the company showcases effective utilization of assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.87.
<h2>How Are Analyst Ratings Determined?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Molina Healthcare Stock: A Deep Dive Into Analyst Perspectives (11 Ratings)

Barclays analyst Andrew Mok maintains Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) with a Equal-Weight and raises the price target from $339 to $362.

Price Target

Barclays Maintains Equal-Weight on Molina Healthcare, Raises Price Target to $362

U.S. equities are pushing higher for a third straight session, eyeing the longest winning streak since the Trump tariff announcement on April 2, as optimism over corporate earnings and easing trade <a href="https://www.benzinga.com/markets">tensions boosts risk sentiment.</a>
Positive quarterly results and robust guidance from U.S. firms is fueling hopes the economy can weather the ongoing tariff headwinds and avoid a recession.
Meanwhile, signs of a potential thaw in the U.S.-China trade conflict emerged, with the White House reportedly considering exceptions for certain Chinese auto parts.
At midday trading in New York, the Nasdaq 100 surged 2.2%, climbing above the 19,000 mark for the first time in two weeks. The S&amp;P 500 advanced 1.5%, while the Dow Jones Industrial Average underperformed, rising 0.9%.
Technology stocks broadly outperformed, with strength concentrated in the Magnificent Seven and the semiconductor space.
Among major movers, ServiceNow Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NASDAQ">NOW</a>) soared 15% after reporting results that beat Wall Street expectations and issuing bullish forward guidance. In contrast, shares of International Business Machines Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>) slumped 8% as the tech giant showed lower-than-expected non-GAAP earnings. 
In the consumer staples sector, Procter &amp; Gamble (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>) dropped more than 5% after missing revenue estimates.
Treasury yields continued to ease, with yields on the 10-year Treasury down 5 basis points to 4.33%. 
Gold rebounded modestly after suffering a 2.7% slide on Wednesday. Natural gas prices extended their losing streak, plunging 4.9% and heading for a tenth consecutive negative session. 
In the crypto market, Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) eased 0.5% to trade at $93,300. 
<h2 class="wp-block-heading">Thursday&#8217;s Performance In Major US Indices, ETFs</h2>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>19,095.73</td>
<td>2.2%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,456.36</td>
<td>1.5%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>1,943.95</td>
<td>1.3%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>39,944.47</td>
<td>0.9%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated by 12:15 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">Benzinga Pro</a>&nbsp;data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) rose 1.5% up to $543.71.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) rose 0.9% to $399.51.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;rallied 2.1% to $464.72.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) rallied 1.5% to $193.08.</li>
<li>The&nbsp;Technology&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>) outperformed, up 3%; the&nbsp;Consumer Staples&nbsp;Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLP#NYSE">XLP</a>) lagged, down 0.8%.</li>
</ul>
<h2 class="wp-block-heading">Thursday&#8217;s Stock Movers</h2>
Stocks reacting to earnings included: 
<ul>
<li>Chipotle Mexican Grill, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMG#NYSE">CMG</a>): up 0.6%</li>
<li>O'Reilly Automotive, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORLY#NASDAQ">ORLY</a>): down 3.1%</li>
<li>Raymond James Financial, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RJF#NYSE">RJF</a>): up 0.7%</li>
<li>Molina Healthcare, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>): down 6.4%</li>
<li>Texas Instruments Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXN#NASDAQ">TXN</a>): up 6.0%</li>
<li>FirstEnergy Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FE#NYSE">FE</a>): up 0.4%</li>
<li>ServiceNow, Inc. up 14.9%</li>
<li>Lam Research Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRCX#NASDAQ">LRCX</a>): up 5.5%</li>
<li>ResMed Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RMD#NYSE">RMD</a>): up 10.0%</li>
<li>Discover Financial Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DFS#NYSE">DFS</a>): up 3.6%</li>
<li>International Business Machines Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>): down 7.6%</li>
<li>Newmont Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEM#NYSE">NEM</a>): up 3.6%</li>
<li>Rollins, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROL#NYSE">ROL</a>): up 1.2%</li>
<li>United Rentals, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/URI#NYSE">URI</a>): up 8.9%</li>
<li>Tyler Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TYL#NYSE">TYL</a>): down 3.0%</li>
<li>Edwards Lifesciences Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>): up 7.1%</li>
<li>Las Vegas Sands Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LVS#NYSE">LVS</a>): up 5.2%</li>
<li>Alaska Air Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALK#NYSE">ALK</a>): down 9.7%</li>
<li>American Airlines Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAL#NASDAQ">AAL</a>): up 2.3%</li>
<li>PepsiCo, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEP#NASDAQ">PEP</a>): down 4.1%</li>
<li>CBRE Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CBRE#NYSE">CBRE</a>): up 2.5%</li>
<li>Entergy Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETR#NYSE">ETR</a>): up 0.4%</li>
<li>The Procter &amp; Gamble Company: down 5.3%</li>
<li>Bristol-Myers Squibb Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>): down 0.2%</li>
<li>Southwest Airlines Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUV#NYSE">LUV</a>): down 0.2%</li>
<li>Valero Energy Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VLO#NYSE">VLO</a>): down 1.8%</li>
<li>Comcast Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCSA#NASDAQ">CMCSA</a>): down 5.3%</li>
<li>Dow Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOW#NYSE">DOW</a>): up 2.1%</li>
<li>Willis Towers Watson Public Limited Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WTW#NASDAQ">WTW</a>): down 5.2%</li>
<li>Tractor Supply Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSCO#NASDAQ">TSCO</a>): down 4.8%</li>
<li>Hasbro, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HAS#NASDAQ">HAS</a>): up 16.1%</li>
<li>CMS Energy Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMS#NYSE">CMS</a>): up 2.3%</li>
<li>Xcel Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XEL#NASDAQ">XEL</a>): down 1.8%</li>
<li>CenterPoint Energy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNP#NYSE">CNP</a>): up 1.8%</li>
<li>LKQ Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LKQ#NASDAQ">LKQ</a>): down 10.7%</li>
<li>PG&amp;E Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PCG#NYSE">PCG</a>): down 0.8%</li>
<li>Keurig Dr Pepper Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KDP#NASDAQ">KDP</a>): down 0.6%</li>
<li>Freeport-McMoRan Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FCX#NYSE">FCX</a>): up 5.5%</li>
<li>Merck &amp; Co., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>): down 0.6%</li>
<li>Nasdaq, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDAQ#NASDAQ">NDAQ</a>): down 0.4%</li>
<li>L3Harris Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LHX#NYSE">LHX</a>): up 0.4%</li>
<li>Pool Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POOL#NASDAQ">POOL</a>): down 6.1%</li>
<li>Dover Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOV#NYSE">DOV</a>): up 1.8%</li>
<li>West Pharmaceutical Services, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>): down 2.2%</li>
<li>Ameriprise Financial, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMP#NYSE">AMP</a>): down 0.2%</li>
<li>Fiserv, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FI#NYSE">FI</a>): down 16.4%</li>
<li>The Interpublic Group of Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IPG#NYSE">IPG</a>): up 3.4%</li>
<li>Allegion plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALLE#NYSE">ALLE</a>): up 9.7%</li>
<li>Union Pacific Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNP#NYSE">UNP</a>): down 3.1%</li>
</ul>
Stocks slated to report earnings after the bell include T-Mobile US, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NASDAQ">TMUS</a>), VeriSign, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRSN#NASDAQ">VRSN</a>), Eastman Chemical Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMN#NYSE">EMN</a>), Principal Financial Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PFG#NASDAQ">PFG</a>), Physicians Realty Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOC#NYSE">DOC</a>), The Hartford Financial Services Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIG#NYSE">HIG</a>), Weyerhaeuser Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WY#NYSE">WY</a>), Republic Services, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RSG#NYSE">RSG</a>), Digital Realty Trust, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DLR#NYSE">DLR</a>), Gilead Sciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>), Erie Indemnity Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ERIE#NASDAQ">ERIE</a>), Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>), and Intel Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>).
Read also: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44985682/apples-ai-delays-rising-cost-pressures-trigger-price-target-cut-from-bank-of-america">Apple AI Delays, Rising Cost Pressures Trigger Price Target Cut From Bank Of America</a></li>
</ul>
Photo: Shutterstock

$BTC

ALLE

CBRE

CMCSA

SPDR Dow Jones Industrial Average ETF Trust

ERIE

GILD

INTC

LRCX

NDAQ

ORLY

POOL

TMUS

TSCO

VRSN

Select Sector SPDR-Consumer Discretionary

Wall Street Rally Extends Into Third Day: What's Driving Markets Thursday?

WIIM

Molina Healthcare shares are trading lower. The company reported Q1 financial results.

2025 Guidance Premium revenue guidance for the full year is unchanged and expected to be approximately $42 billion, an increase of approximately 9% from the full year 2024.
The Company expects its full year GAAP earnings in 2025 to be at least $22.32 per share and reaffirms its full year adjusted earnings in 2025 to be at least $24.50 per share, representing 8% growth over the full year 2024.

Molina Healthcare FY2025 Expected To Be More Than $24.50 vs $24.48 Est

Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) reported quarterly earnings of $6.08 per share which beat the analyst consensus estimate of $5.96 by 2.01 percent. This is a 6.11 percent increase over earnings of $5.73 per share from the same period last year. The company reported quarterly sales of $11.15 billion which beat the analyst consensus estimate of $10.81 billion by 3.16 percent. This is a 12.24 percent increase over sales of $9.93 billion the same period last year.

Earnings

Molina Healthcare Q1 Adj. EPS $6.08 Beats $5.96 Estimate, Sales $11.15B Beat $10.81B Estimate

Risk-on sentiment dominated Wall Street on Wednesday, as upbeat earnings reports and conciliatory messages from the Trump administration h<a href="https://www.benzinga.com/markets">elped lift investor confidence.</a>
The administration eased market fears on two major fronts that have recently weighed heavily on sentiment. On the trade front, tensions with China appeared to thaw, with reports suggesting the White House is considering reducing tariffs on certain categories of goods.
U.S. Treasury Secretary Scott Bessent added fuel to the rally, stating U.S.-China tariffs are unsustainable and will likely need to be lowered to facilitate meaningful negotiations.
Meanwhile, President Donald Trump offered an abrupt shift in tone toward Federal Reserve Chair Jerome Powell, saying he has no intention to fire him, a remark that helped calm concerns over political interference in monetary policy.
By midday in New York, the S&amp;P 500 was up by nearly 2%, though it had earlier climbed even higher. The Nasdaq 100 outperformed with a 2.5% gain, driven by strength in Magnificent Seven stocks.
Trump's pivot on Powell pushed Treasury yields lower across the curve, with the 30-year yield falling five basis points to 4.83%, after briefly topping 4.90% the previous day.
On the macro front, flash Purchasing Managers&#8217; Index surveys revealed slowing growth momentum in the U.S. economy, as the services sector decelerated sharply following the impact <a href="https://www.benzinga.com/government/regulations/25/04/44952395/us-business-activity-growth-slows-in-april-as-services-suffer-tariff-shock-markets-rally-as-trade-war-cools">of recent tariff shocks.</a>
The U.S. dollar strengthened, while gold plunged 2.6%, heading for its worst session since November.
Oil prices dropped more than 2% following speculation that OPEC+ may announce a new output hike as early as next month.
Meanwhile, Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) held steady around $93,000.
<h1 class="wp-block-heading">Wednesday&#8217;s Performance In Major U.S. Indices, ETFs</h1>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>Chg</td>
<td>1-day %</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>18,732.09</td>
<td>+455.68</td>
<td>2.5%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>1,926.45</td>
<td>+37.40</td>
<td>2.0%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,384.67</td>
<td>+96.91</td>
<td>1.8%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>39,724.87</td>
<td>+537.89</td>
<td>1.4%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 12:35 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">Benzinga Pro</a>&nbsp;data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) rose 1.9% to $537.35.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) rose 1.4% to $397.79.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;rallied 2.7% to $456.50.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) soared 2.1% to $191.47.</li>
<li>The&nbsp;Technology&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>) outperformed, up 3.44%; the&nbsp;Consumer Staples&nbsp;Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLP#NYSE">XLP</a>) lagged, down 1.2%.</li>
</ul>
<h1 class="wp-block-heading">Wednesday&#8217;s Stock Movers</h1>
<ul>
<li>Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) jumped 6.6% despite falling short on both earnings and revenue expectations, as CEO Elon Musk reassured investors by pledging to scale back his involvement with DOGE and refocus on the company.</li>
</ul>
Other stocks reacting to earnings report included: 
<ul>
<li>Intuitive Surgical Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>): up 2.8%</li>
<li>Chubb Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CB#NYSE">CB</a>): down 2.6%</li>
<li>Capital One Financial Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COF#NYSE">COF</a>): up 4.6%</li>
<li>Steel Dynamics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STLD#NASDAQ">STLD</a>): up 4.7%</li>
<li>EQT Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQT#NYSE">EQT</a>): up 3%</li>
<li>Packaging Corporation of America (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PKG#NYSE">PKG</a>): down 1.7%</li>
<li>Baker Hughes Co. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKR#NASDAQ">BKR</a>): down 4.3%</li>
<li>Enphase Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>): down 14.4%​</li>
<li>Thermo Fisher Scientific Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>): down 0.5%</li>
<li>Philip Morris International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PM#NYSE">PM</a>): up 2.6%</li>
<li>NextEra Energy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEE#NYSE">NEE</a>): up 1%</li>
<li>Boston Scientific Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>): up 4.8%</li>
<li>General Dynamics Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GD#NYSE">GD</a>): down 3.4%</li>
<li>Boeing Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>): up 5.7%</li>
<li>Norfolk Southern Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NSC#NYSE">NSC</a>): up 1.4%</li>
<li>CME Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CME#NASDAQ">CME</a>): down 3.8%</li>
<li>TE Connectivity Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEL#NYSE">TEL</a>): up 2.7%</li>
<li>Amphenol Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APH#NYSE">APH</a>): up 9.9%</li>
<li>AT&amp;T Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/T#NYSE">T</a>): up 0.8%</li>
<li>Old Dominion Freight Line, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODFL#NASDAQ">ODFL</a>): up 1.3%</li>
<li>Westinghouse Air Brake Technologies Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAB#NYSE">WAB</a>): up 7.2%</li>
<li>Masco Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAS#NYSE">MAS</a>): down 2.1%</li>
<li>Avery Dennison Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVY#NYSE">AVY</a>): down 2.4%</li>
<li>Lennox International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LII#NYSE">LII</a>): down 8.2%</li>
<li>GE Vernova Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEV#NYSE">GEV</a>): up 5.2%</li>
<li>Teledyne Technologies Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDY#NYSE">TDY</a>): down 1.7%</li>
<li>Otis Worldwide Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OTIS#NYSE">OTIS</a>): down 6%​</li>
</ul>
<ul>
<li>Stocks slated to report earnings after the bell include Chipotle Mexican Grill, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMG#NYSE">CMG</a>), O'Reilly Automotive, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORLY#NASDAQ">ORLY</a>), Raymond James Financial, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RJF#NYSE">RJF</a>), Molina Healthcare, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>), Texas Instruments Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXN#NASDAQ">TXN</a>), FirstEnergy Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FE#NYSE">FE</a>), ServiceNow, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>), Lam Research Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRCX#NASDAQ">LRCX</a>), Resmed Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RMD#NYSE">RMD</a>), Discover Financial Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DFS#NYSE">DFS</a>), International Business Machines Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>), Newmont Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEM#NYSE">NEM</a>), Rollins Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROL#NYSE">ROL</a>), United Rentals Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/URI#NYSE">URI</a>), Tyler Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TYL#NYSE">TYL</a>), Edwards Lifesciences Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>), Las Vegas Sands Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LVS#NYSE">LVS</a>), and Alaska Air Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALK#NYSE">ALK</a>).</li>
</ul>
Read Now: 
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/04/44948932/goldman-sachs-backs-copper-tariff-trade-if-trump-slaps-25-duty-on-us-imports">Goldman Sachs Backs &#8216;Copper Tariff Trade&#8217; If Trump Slaps 25% Duty On US Imports</a></li>
</ul>
Photo: Shutterstock

Government

Macro Economic Events

Regulations

Broad U.S. Equity ETFs

Economics

Federal Reserve

Tech

ETFs

ENPH

ISRG

ODFL

OTIS

STLD

TSLA

Stocks Surge On China Tariff Hopes, Tesla Jumps, Gold Loses Shine: What's Driving Markets Wednesday?

AMTB

ASGN

BANC

BPOP

BRKL

BWFG

CACI

CBAN

CHDN

CHKP

COOP

CSLR

CVLG

New Oriental Education & Technology Group

EGBN

EPRT

GATX

GLPG

GSHD

HBNC

HCSG

IMAX

INBK

KALU

KREF

MTDR

OSBC

PLXS

PTEN

SEIC

Earnings Scheduled For April 23, 2025

Bernstein analyst Lance Wilkes initiates coverage on Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) with a Outperform rating and announces Price Target of $414.

Initiation

Bernstein Initiates Coverage On Molina Healthcare with Outperform Rating, Announces Price Target of $414

Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) is set to give its latest quarterly earnings report on Wednesday, 2025-04-23. Here's what investors need to know before the announcement.
Analysts estimate that Molina Healthcare will report an earnings per share (EPS) of $6.58. 
Molina Healthcare bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Overview of Past Earnings</h3>
In the previous earnings release, the company missed EPS by $0.83, leading to a 10.09% drop in the share price the following trading session.
Here's a look at Molina Healthcare's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>5.88</td>
<td>5.94</td>
<td>5.55</td>
<td>5.59</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>5.05</td>
<td>6.01</td>
<td>5.86</td>
<td>5.73</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-10.0%</td>
<td>18.0%</td>
<td>12.0%</td>
<td>-4.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745334211_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Molina Healthcare were trading at $302.09 as of April 21. Over the last 52-week period, shares are down 15.87%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<h3>Analysts' Take on Molina Healthcare</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Molina Healthcare.
A total of 9 analyst ratings have been received for Molina Healthcare, with the consensus rating being Neutral. The average one-year price target stands at $363.56, suggesting a potential 20.35% upside.
<h3>Peer Ratings Comparison</h3>
The analysis below examines the analyst ratings and average 1-year price targets of HealthEquity, Centene and Alignment Healthcare, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Outperform trajectory for HealthEquity, with an average 1-year price target of $111.11, suggesting a potential 63.22% downside.</li>
<li>Analysts currently favor an Neutral trajectory for Centene, with an average 1-year price target of $68.33, suggesting a potential 77.38% downside.</li>
<li>Analysts currently favor an Buy trajectory for Alignment Healthcare, with an average 1-year price target of $18.19, suggesting a potential 93.98% downside.</li>
</ul>
<h3>Overview of Peer Analysis</h3>
In the peer analysis summary, key metrics for HealthEquity, Centene and Alignment Healthcare are highlighted, providing an understanding of their respective standings within the industry and offering insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molina Healthcare</td>
<td>Neutral</td>
<td>16.04%</td>
<td>$1.11B</td>
<td>5.42%</td>
</tr>
<tr>
<td>HealthEquity</td>
<td>Outperform</td>
<td>18.84%</td>
<td>$189.04M</td>
<td>1.24%</td>
</tr>
<tr>
<td>Centene</td>
<td>Neutral</td>
<td>3.41%</td>
<td>$3.72B</td>
<td>1.05%</td>
</tr>
<tr>
<td>Alignment Healthcare</td>
<td>Buy</td>
<td>50.68%</td>
<td>$86.34M</td>
<td>-29.00%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Molina Healthcare ranks in the middle for consensus rating. It ranks at the bottom for revenue growth. It ranks at the top for gross profit. It ranks at the bottom for return on equity.
<h3>Unveiling the Story Behind Molina Healthcare</h3>
Molina Healthcare Inc offers healthcare plans focused on Medicaid-related solutions for low-income families and individuals. Its health plans are operated by a network of subsidiaries, each of which is licensed as a health maintenance organization (HMO). It has four segments: Medicaid, Medicare, Marketplace and Others. The Medicaid, Medicare, and Marketplace segments represent the government-funded or sponsored programs under which it offers managed healthcare services. The Other segment, which is insignificant to its consolidated results of operations, includes long-term services and supports consultative services in Wisconsin. It generates majority revenue from Medicaid segment.
<h3>Molina Healthcare: A Financial Overview</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Positive Revenue Trend: Examining Molina Healthcare's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 16.04% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Molina Healthcare's net margin is impressive, surpassing industry averages. With a net margin of 2.39%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Molina Healthcare's ROE excels beyond industry benchmarks, reaching 5.42%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.6%, the company showcases effective utilization of assets.
Debt Management: Molina Healthcare's debt-to-equity ratio is below the industry average at 0.69, reflecting a lower dependency on debt financing and a more conservative financial approach.
<a href="https://www.benzinga.com/quote/MOH/earnings">To track all earnings releases for Molina Healthcare visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Look at Molina Healthcare's Upcoming Earnings Report

ALHC

Shares of health insurance stocks are trading lower in sympathy with UnitedHealth, which reported worse-than-expected Q1 results and cut its FY25 adjusted EPS guidance below estimates on Thursday.

Shares of health insurance stocks are trading lower in sympathy with UnitedHealth, which reported worse-than-expected Q1 results and cut its FY25 adjusted EPS guidance below estimates.

Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) has outperformed the market over the past 20 years by 5.02% on an annualized basis producing an average annual return of 12.85%. Currently, Molina Healthcare has a market capitalization of $18.18 billion. 
Buying $100 In MOH: If an investor had bought $100 of MOH stock 20 years ago, it would be worth $1,139.07 today based on a price of $332.38 for MOH at the time of writing.
<h3>Molina Healthcare's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744835413_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $100 In This Stock 20 Years Ago, You Would Have This Much Today

Molina Healthcare shares are trading lower after Baird downgraded the stock from Outperform to Neutral.

Wall Street gained ground by midday trading on Tuesday, as investor concerns over the economic impact of trade tensions continued to ease following recent signs that the Trump administration was taking <a href="https://www.benzinga.com/government/regulations/25/04/44812727/bessent-says-tariffs-on-china-are-far-from-a-joke-dismisses-treasury-dumping-fears">a more conciliatory approach.</a>
All major indexes were in positive territory, with tech stocks leading the way thanks to strong performances by Netflix Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) and Palantir Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>), both rising about 6%.
The streaming giant climbed following a <a href="https://www.wsj.com/business/media/netflix-aims-to-join-the-1-trillion-club-fdacb250">Wall Street Journal report</a> that it plans to double revenue by 2030, citing sources. Netflix is set to release its first-quarter earnings on Thursday after market close.
The S&amp;P 500 has now recovered nearly 80% of the losses suffered after Trump's tariff announcement on April 2.
Among sectors, financials led the gains, climbing 1.3%, supported by strong earnings reports from Bank of America Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>) and Citigroup Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/C#NYSE">C</a>), which surged 4.3% and 3.8%, respectively.
The U.S. Dollar Index (DXY) rebounded 0.5%, aiming to end a five-day losing streak, while Treasury yields declined further, easing fears of a potential sell-off of U.S. assets by foreign investors. Yields on the 10-year Treasury fell five basis points to 4.33%, following an 11-basis-point drop on Monday.
In commodities, gold edged up 0.4% to $3,223 per ounce, while oil prices slipped 0.8% to $61 per barrel. Natural gas dropped 1.6% to $3.25 per million British thermal units, approaching its lowest level since mid-December 2024.
Crypto markets remained relatively quiet, with Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) rising 0.5% to $85,000.
<h1 class="wp-block-heading">Tuesday&#8217;s Performance In Major U.S. Indices, ETFs</h1>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day chg %</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>18,934.51</td>
<td>0.7%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>1,888.28</td>
<td>0.4%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,424.34</td>
<td>0.3%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>40,639.56</td>
<td>0.3%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 12:20 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">Benzinga Pro</a>&nbsp;data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) rose 0.3% to $540.87.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) inched 0.1% higher to $405.36.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;increased 0.7% to $460.14.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) edged 0.4% higher to $187.22.</li>
<li>The&nbsp;Financial&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>) outperformed, up 1.3%; the&nbsp;Health Care&nbsp;Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>) lagged, down 0.5%.</li>
</ul>

<h1 class="wp-block-heading">S&amp;P 500&#8217;s Top 5 Gainers On Monday</h1>
<figure class="wp-block-table is-style-stripes"> 
<table>
<thead>
<tr>
<th>Company</th>
<th>% Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Netflix, Inc. </td>
<td>5.88%</td>
</tr>
<tr>
<td>Palantir Technologies Inc.</td>
<td>5.18%</td>
</tr>
<tr>
<td>Hewlett Packard Enterprise Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPE#NYSE">HPE</a>)</td>
<td>4.87%</td>
</tr>
<tr>
<td>CrowdStrike Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>)</td>
<td>4.53%</td>
</tr>
<tr>
<td>Bank of America Corporation </td>
<td>4.38%</td>
</tr>
</tbody>
</table>
</figure>
<h1 class="wp-block-heading">S&amp;P 500&#8217;s Worst 5 Losers On Monday</h1>
<figure class="wp-block-table is-style-stripes"> 
<table>
<thead>
<tr>
<th>Company</th>
<th>% Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Albemarle Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALB#NYSE">ALB</a>)</td>
<td>-4.25%</td>
</tr>
<tr>
<td>Molina Healthcare, Inc. (NYSE: МОH)</td>
<td>-3.66%</td>
</tr>
<tr>
<td>Zimmer Biomet Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>)</td>
<td>-3.14%</td>
</tr>
<tr>
<td>Moderna, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>)</td>
<td>-2.94%</td>
</tr>
<tr>
<td>The Campbell&#8217;s Company (NYSE: СРB)</td>
<td>-2.75%</td>
</tr>
</tbody>
</table>
</figure>
Read Now: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/04/44817677/citigroup-ceo-jane-fraser-bets-us-will-still-be-worlds-leading-economy-and-dollar-the-reserve-currency-after-trade-uncertainty-settles">Citigroup CEO Jane Fraser Bets US Will &#8216;Still Be World&#8217;s Leading Economy&#8217; And Dollar &#8216;The Reserve Currency&#8217; After Trade Uncertainty Settles</a></li>
</ul>

Mid Cap

Sector ETFs

Econ #s

CRWD

MRNA

NFLX

PLTR

Stocks Edge Up On Strong Bank Earnings, Netflix Soars, Dollar Rebounds: What's Driving Markets Tuesday?

Baird analyst Michael Ha downgrades Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) from Outperform to Neutral and raises the price target from $331 to $375.

Downgrades

Baird Downgrades Molina Healthcare to Neutral, Raises Price Target to $375

Truist Securities analyst David Macdonald maintains Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) with a Buy and raises the price target from $340 to $400.

Truist Securities Maintains Buy on Molina Healthcare, Raises Price Target to $400

In the last three months, 7 analysts have published ratings on Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>), offering a diverse range of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Molina Healthcare, presenting an average target of $356.71, a high estimate of $400.00, and a low estimate of $325.00. Experiencing a 0.68% decline, the current average is now lower than the previous average price target of $359.14. 
<img src="https://www.benzinga.com/files/images/story/2025/1744225222_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
A comprehensive examination of how financial experts perceive Molina Healthcare is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Ann Hynes &#x7C;Mizuho &#x7C;Raises &#x7C;Outperform &#x7C; $400.00&#x7C;$376.00 &#x7C; 
&#x7C;Stephen Baxter &#x7C;Wells Fargo &#x7C;Raises &#x7C;Overweight &#x7C; $372.00&#x7C;$295.00 &#x7C; 
&#x7C;Ann Hynes &#x7C;Mizuho &#x7C;Lowers &#x7C;Outperform &#x7C; $376.00&#x7C;$382.00 &#x7C; 
&#x7C;David Macdonald &#x7C;Truist Securities &#x7C;Lowers &#x7C;Buy &#x7C; $340.00&#x7C;$370.00 &#x7C; 
&#x7C;Andrew Mok &#x7C;Barclays &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $339.00&#x7C;$372.00 &#x7C; 
&#x7C;Kevin Caliendo &#x7C;UBS &#x7C;Lowers &#x7C;Neutral &#x7C; $325.00&#x7C;$374.00 &#x7C; 
&#x7C;Raj Kumar &#x7C;Stephens &amp; Co. &#x7C;Maintains &#x7C;Equal-Weight &#x7C; $345.00&#x7C;$345.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Molina Healthcare. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Molina Healthcare compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Molina Healthcare's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Molina Healthcare's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/MOH/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Molina Healthcare analyst ratings.</a>
<h2>About Molina Healthcare</h2>
Molina Healthcare Inc offers healthcare plans focused on Medicaid-related solutions for low-income families and individuals. Its health plans are operated by a network of subsidiaries, each of which is licensed as a health maintenance organization (HMO). It has four segments: Medicaid, Medicare, Marketplace and Others. The Medicaid, Medicare, and Marketplace segments represent the government-funded or sponsored programs under which it offers managed healthcare services. The Other segment, which is insignificant to its consolidated results of operations, includes long-term services and supports consultative services in Wisconsin. It generates majority revenue from Medicaid segment.
<h3>Molina Healthcare: Delving into Financials</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3M period, Molina Healthcare showcased positive performance, achieving a revenue growth rate of 16.04% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Molina Healthcare's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 2.39%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Molina Healthcare's ROE stands out, surpassing industry averages. With an impressive ROE of 5.42%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Molina Healthcare's ROA stands out, surpassing industry averages. With an impressive ROA of 1.6%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Molina Healthcare's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.69.
<h2>How Are Analyst Ratings Determined?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

7 Analysts Have This To Say About Molina Healthcare

Press Releases

Molina Healthcare Announces Proposed Offering of $500 Million of Senior Notes Due 2033

Molina Healthcare Announces Pricing of $750 Million of 6.250% Senior Notes Due 2033

Molina Healthcare Announces Closing of Offering of $750 Million of 6.250% Senior Notes Due 2033

Molina Healthcare Awarded Contracts to Serve Dual Eligible Populations in Michigan and Idaho

Molina Healthcare Announces Fourth Quarter and Year-End 2024 Earnings Release and Conference Call Dates

Molina Healthcare Announces the Closing of its Acquisition of ConnectiCare

Molina Healthcare Reports Fourth Quarter and Year-End 2024 Financial Results

Molina Healthcare Announces First Quarter 2025 Earnings Release and Conference Call Dates

Molina Healthcare Wins Illinois Contract to Provide a Dual Eligible Special Needs Plan

Molina Healthcare Reports First Quarter 2025 Financial Results

Alignment Healthcare, Inc. - Common Stock

Alignment Healthcare

Clover Health Investments, Corp. - Class A Common stock

Clover Health Investments

Centene

Elevance Health

HealthEquity

NeueHealth

Progyny

UnitedHealth Group Incorporated Common Stock (DE)

UnitedHealth Group

Barclays

Bernstein

Baird

Truist Securities

Mizuho

지난주 3월 31일부터 4월 4일까지 S&amp;P 500 지수는 약 9.1% 하락했으며 이는 벤치마크 지수로서 최악의 주간 실적 중 하나로 기록되었다. 하지만 전반적인 시장 매도세 속에서도 상승한 대형주가 있었다.
<ol>
<li>코어위브(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWV#NASDAQ">CRWV</a>): 알파벳(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>)(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>)의 구글이 엔비디아(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)의 블랙웰 칩을 임대하려 한다는 보도가 나오면서 지난주 19.55% 상승했다.</li>
<li>로켓 컴퍼니스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RKT#NYSE">RKT</a>): 키프, 브루옛 &amp; 우즈(Keefe, Bruyette and Woods)에서 투자 의견을 시장수익률 하회에서 시장수익률 등급으로 상향 조정하고, <a href="https://www.benzinga.com//node/44612611" target="_blank" rel="noreferrer noopener">목표주가를 12달러에서 14달러로 상향했다는 소식</a>에 18.19% 급등했다.</li>
<li>게임스탑(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>): 1.5억 달러의 사모펀드 조달 후 <a href="https://www.benzinga.com//node/44638041" target="_blank" rel="noreferrer noopener">라이언 코헨(Ryan Cohen) CEO가 회사 지분을 확대했다</a>는 소식에 8.10% 상승했다.</li>
<li>달러 제너럴(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DG#NYSE">DG</a>): 지난주 7.58% 상승했다. 소비재 주식의 주가가 상승한 것은 관세 불확실성이 <a href="https://www.benzinga.com//node/44641614" target="_blank" rel="noreferrer noopener">방어주로의 이동을 유도할 수 있기 때문</a>이었다.</li>
<li>몰리나 헬스케어(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>): 지난주 7.39% 증가했다. 몰리나 헬스케어는 최근 <a style="font-size: revert;" href="https://www.benzinga.com//node/44634528">거래 가능한</a> 모든 보통주의 4.16%인 175만 주가 공매도되었다고 보고했다.</li>
<li>필그림스 프라이드(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PPC#NASDAQ">PPC</a>): 지난주 5.63% 상승했다.</li>
<li>로스 스토어스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROST#NASDAQ">ROST</a>): 지난주 3.90% 상승했다. 시티그룹 애널리스트 폴 레주즈(Paul Lejuez)는 로스 스토어스 투자의견을 중립에서 <a href="https://www.benzinga.com/quote/rost/analyst-ratings" target="_blank" rel="noreferrer noopener">매수로 상향 조정하고 146달러의 목표주가를 제시했다</a>.</li>
<li>부즈 앨런 해밀턴(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAH#NYSE">BAH</a>): 지난주 3.72% 상승했다.</li>
<li>TJX 컴퍼니스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TJX#NYSE">TJX</a>): 지난주 3.34% 증가했다. 시티그룹 애널리스트 폴 레주즈는 TJX 컴퍼니스 투자의견을 중립에서 매수로 상향하고 <a href="https://www.benzinga.com/quote/tjx/analyst-ratings" target="_blank" rel="noreferrer noopener">목표주가를 128달러에서 140달러로 상향 조정했다.</a></li>
<li>NVR(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVR#NYSE">NVR</a>): 국채수익률 하락 속 지난주 3.19% 증가했다.</li>
</ol>
이미지 출처: Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 수익률을 높이세요.
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

시그나 그룹(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>), 몰리나 헬스케어(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>), 유나이티드헬스 그룹(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) 같은 <a href="https://www.benzinga.com/insights/options/25/02/43981978/10-health-care-stocks-whale-activity-in-todays-session" target="_blank" rel="noopener">주요 의료 서비스 회사들의 주가</a>는 도널드 트럼프 대통령이 헬스케어 산업의 가격 투명성 규제를 강화하기 위한 행정명령에 서명한 이후 수요일(26일) 하락했다.
알아둘 내용: 2월 25일에 서명된 이 행정명령은 재무부, 노동부, 보건복지부를 포함한 연방 기관에 병원과 보험사가 의료 서비스의 실제 비용을 공개하도록 요구하는 2019년 규칙을 시행하고 확대할 것을 지시한다. 이 계획은 가격 기밀을 없애고 소비자에게 의료 서비스 비용에 대한 명확한 정보를 제공하기 위한 것이라고 로이터 통신은 전했다.
2019년 초반의 규칙은 병원이 소비자 친화적인 형식으로 최대 300가지의 구매 가능한 서비스에 대한 가격 정보를 표시하고, 제공되는 모든 서비스에 대한 협상된 요금의 기계 판독 가능 파일을 유지하도록 요구했다. 또한, 건강보험 회사는 의료 서비스 제공자와의 협상된 요금, 네트워크 외부 지불, 그리고 처방약에 대해 본인 또는 약국 혜택 관리자가 지불하는 실제 비용을 공개하도록 의무화했다.
투명성에 대한 새로운 요구는 투자자들 사이에서 더 엄격한 집행이 병원과 보험사의 매출에 영향을 미칠 수 있다는 우려를 불러일으켰다. 헬스케어 서비스 회사들이 예상 가격이 아닌 실제 가격을 공개해야 하는 상황에서, 보험사가 헬스케어 서비스 제공자와 더 낮은 요율을 협상해야 한다는 압박을 받을 수 있다는 추측이 제기되고 있으며, 이는 잠재적으로 수익 마진에 영향을 미칠 수 있다.
주가 움직임: <a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2" target="_blank" rel="noopener">Benzinga Pro에</a> 따르면, 시그나 그룹의 주가는 2.73% 하락한 305.34달러, 몰리나 헬스케어는 6.95% 하락한 284.71달러, 유나이티드헬스 그룹은 1.44% 하락한 463.59달러로 마감했다.
이미지 출처: Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 수익률을 높이세요.
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

미국의 의료 보험 회사 휴매나(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>)의 주식은 수요일 소폭 상승 마감했다. 화요일 이 회사는 4분기 조정 주당순이익이 2.16달러 손실이라고 발표했다. 이는 전년 대비 11센트 감소한 수치로, <a href="https://www.benzinga.com/earnings" target="_blank" rel="noreferrer noopener">컨센서스와 일치</a>하며 <a href="https://www.benzinga.com/government/regulations/25/01/43173248/us-health-agency-cms-to-appeal-medicare-star-ratings-recalculation-ruling" target="_blank" rel="noreferrer noopener">별 등급제에 대한 추가 투자</a>를 포함한 것이다.
이 회사는 매출이 291억 9천만 달러로, 전년 대비 257억 3천만 달러에서 13.5% 증가하여 <a href="https://www.benzinga.com/25/02/43621782/insurance-giant-humanas-q4-earnings-at-par-with-estimates-2025-profit-outlook-falls-below-street-view" target="_blank" rel="noreferrer noopener">컨센서스 288억 4천만 달러</a>를 초과했다고 보고했다.
휴매나는 2025년 보험 부문의 손익 비율 가이던스를 약 90.1-90.5%로 예상하고 있다.
또한 읽어보기: <a href="https://www.benzinga.com/general/health-care/25/01/43321236/rfk-jr-and-big-pharma-stocks-to-watch-as-health-secretary-hopeful-answers-pointed-questions-on-drugs-insurance-trump-exec-orders" target="_blank" rel="noreferrer noopener">RFK Jr.와 대제약사: 보건부 장관 후보가 약물, 보험, 트럼프 행정명령에 대한 날카로운 질문에 답변</a>
캔터 피츠제럴드는 비용 추세 가정에 대해 보다 신중한 접근을 예상한다. 그러나 애널리스트인 사라 제임스(Sarah James)와 가비 잉골리아(Gabie Ingoglia)는 일부 조정이 필요하다는 논리에는 동의한다.
&#8220;우리는 비용 추세에 대한 이례적인 가정에 대해 우려를 가지고 있으나, 그 논리에는 일정 부분 타당성이 있다고 생각한다. 또한, 시장이 2026년과 2027년에 그룹 MA 상품을 회복하는 데 있어 이익 잠재력을 과소평가하고 있을 수 있다고 믿고 있다. 이는 2025년에는 $1-2의 이익 감소 요인으로 작용할 수 있다&#8221;라고 이 애널리스트들이 언급했다.
휴매나는 2025년 비용 추세가 중간 단일 자릿수로 둔화될 것으로 예상하는 점에서 두드러진다. 이는 2024년의 높은 단일 자릿수와 대조적이다. 반면, 유나이티드헬스 그룹(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), 엘레반스 헬스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>) 및 몰리나 헬스케어(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>)는 2024년부터 계속해서 높은 추세가 유지될 것으로 예상하고 있다.
휴매나는 2025년에는 반복되지 않을 요인, 즉 &#8220;두 자정&#8221; 규정의 영향을 기대하며, 여전히 높은 전문 약품 비용을 예상하고 있다. 이 회사는 또한 2024년 3분기에서 4분기까지 안정적인 비용 추세가 유지되지만, 연말 이용률을 증가시키는 보충 혜택의 계절적 증가가 있다고 언급했다.
경영진은 비용을 공격적으로 절감할 계획이며, AEP 결과는 회사의 가격 책정 전략이 효과를 보고 있음을 확인한다. 그러나 이 회사는 재심사로 인해 약 30,000명의 D-SNP 회원을 잃었다.
또 다른 긍정적인 점은 PDP 가격 책정 전략이 문제에 직면하지 않고 있다는 것이다.
가격 동향: 휴매나의 주식은 수요일 0.76% 상승 260.03달러에 마감되었다.
다음 읽기:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/02/43662901/why-is-nano-cap-cancer-focused-xilio-therapeutics-stock-trading-over-100-on-wednesday" target="_blank" rel="noreferrer noopener">왜 나노-캡 암 중심의 자일리오 테라퓨틱스 주식이 수요일에 100% 이상 거래되고 있나요?</a></li>
</ul>
이미지 출처: Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

2008년 금융 위기를 예측한 것으로 유명한 헤지펀드 매니저인 마이클 버리(Michael Burry)는 2008년 금융 위기를 예측한 것으로 유명한 헤지펀드 매니저로, 최근 중국 기술 기업에 대한 노출을 크게 늘렸으며 동시에 잠재적 하방 위험에 대한 보호 조치를 시행했다고 <a href="https://www.benzinga.com/markets/asia/24/11/42000692/david-teppers-appaloosa-trims-alibaba-stake-by-476-in-q3-2024-doubles-down-on-pdd-holdings-and-jd.com">규제 공시</a>에서 밝혔다.
무슨 일이 있었나: 버리의 사이언 에셋 매니지먼트(Scion Asset Management)는 3분기 동안 포트폴리오에 몇 가지 주목할 만한 조정을 했으며, 이제 중국 기업들이 가장 큰 비중을 차지하고 있다. 이 회사는 알리바바 그룹 홀딩(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>)의 지분을 29% 늘려 9월 말 기준으로 2,100만 달러 이상의 가치로 펀드의 최대 보유 종목으로 만들었다.
비슷한 방식으로, 사이언은 JD닷컴(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>)의 지분을 두 배로 늘려 약 2,000만 달러로 펀드의 두 번째 대형 보유 종목으로 만들었다. 또한, 중국 검색 거대 기업인 바이두(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>)에 대한 투자도 67% 증가시켜 1,320만 달러에 달했다.
하지만, 버리는 이러한 보유 종목에 대한 풋 옵션을 동시에 설정하여 조심스러운 전략을 취한 것으로 보인다. 풋 옵션은 기초 증권의 가치가 하락할 때 가치가 상승하는 경향이 있어, 시장 변동성에 대한 보호 전략으로 해석된다.
이러한 움직임은 베이징이 세계에서 두 번째로 큰 경제 성장률을 회복하기 위한 최근 경제 부양책 발표와 동시에 이루어졌다. 중국 주식은 이러한 신호가 나타난 후 9월에 처음으로 반등했지만, 투자자들이 더 구체적인 재정 조치를 기다리면서 상승폭은 완화되었다.
중국 기술 중심 외에도, 버리는 시프트4 페이먼츠(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FOUR#NYSE">FOUR</a>), 아메리칸 코스탈 인슈어런스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACIC#NASDAQ">ACIC</a>) 및 몰리나 헬스케어(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>)와 같은 여러 미국 기업에 대한 포지션도 늘렸다.
중요한 이유는: 버리의 <a href="https://www.benzinga.com/markets/equities/24/10/41248334/big-short-investor-michael-burrys-china-bet-pays-off-as-top-picks-surge-nearly-60-in-2-months">상위 세 개의 중국 보유 종목</a>은 두 달 동안 평균적으로 약 60%의 수익률을 기록했다고 한다.
버리의 움직임은 그의 트랙레코드를 고려할 때 시장 참여자들에 의해 면밀히 주시되고 있다. 그는 2008년 세계 금융 위기 이전에 모기지 담보 증권에 대한 선견지명이 있는 베팅으로 널리 알려졌으며, 이 이야기는 나중에 마이클 루이스의 베스트셀러 &#8220;빅 쇼트&#8221;와 그 후속 아카데미상 수상 영화로 기록되었다.
이러한 포지션은 9월 30일 기준으로 미 증권거래위원회(SEC) 규정에 따라 1억 달러 이상의 자산을 관리하는 펀드에 요구되는 보유 종목을 반영한다. 45일의 보고 지연과 버리의 적극적인 거래 스타일을 고려할 때, 현재 포지션은 이미 변경되었을 수 있다.
이러한 전개는 다른 <a href="https://www.benzinga.com/markets/asia/24/11/42000692/david-teppers-appaloosa-trims-alibaba-stake-by-476-in-q3-2024-doubles-down-on-pdd-holdings-and-jd.com">저명한 투자자들이 중국 보유 종목을 조정하는 것과</a> 동시에 일어났다. 억만장자 투자자 데이비드 테퍼의 아팔루사 매니지먼트는 최근 알리바바 지분을 5% 줄였지만, 여전히 펀드의 최대 보유 종목으로 67억 달러 포트폴리오의 15.75%를 차지하고 있다.

다음 읽기:
<ul>
<li><a href="https://www.benzinga.com/content/41999311/jim-cramer-says-these-10-frothy-stocks-are-up-over-200-ytd-including-rocket-lab-palantir-and-carvana">짐 크레이머가 올 해 200% 이상 상승한 &#8216;거품 주식&#8217; 10개를 언급하다: 로켓랩, 팔란티어, 카바나 포함</a></li>
</ul>
이미지 출처: Shutterstock
면책 조항:이 콘텐츠는 AI 도구의 도움으로 부분적으로 제작되었으며, 벤징가 편집자에 의해 검토 및 게시되었습니다.
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Global

Markets

ACIC

BABA

BIDU

FOUR

'빅 쇼트' 투자자 마이클 버리, 중국 기술주에 베팅 확대하면서 보호 헤지 추가

이들 10개 대형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
1. 테슬라(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)의 주식은 실적 <a href="https://www.benzinga.com//node/41537560" target="_blank" rel="noreferrer noopener">호조와 전반적인 시장 강세</a>로 인해 21.97% 상승했다.
2. 리 오토(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LI#NASDAQ">LI</a>)의 주식은 중국 인민은행이 <a href="https://www.benzinga.com//node/41547149" target="_blank" rel="noreferrer noopener">7,000억 위안</a>($9,836억 달러)를 은행 시스템에 주입하고 금리를 2.0%로 유지한 후 14.02% 상승했다.
3. 몰리나 헬스케어(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>)의 주식은 회사가 <a href="https://www.benzinga.com//node/41500855" target="_blank" rel="noreferrer noopener">3분기 실적을 발표</a>한 후 12.36% 급등했다.
4. 태피스트리(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPR#NYSE">TPR</a>)의 주식은 자사의 카프리 홀딩스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPRI#NYSE">CPRI</a>) 인수 제안이 <a href="https://www.benzinga.com//node/41550527" target="_blank" rel="noreferrer noopener">법원에 의해 차단되었다는 보도</a> 이후 11.83% 상승했다. 이 회사는 이 결정에 대해 항소할 계획이라고 밝혔다.
5. 앱러빈(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>)의 주식은 여러 애널리스트들이 주가 전망을 <a href="https://www.benzinga.com/quote/APP/analyst-ratings" target="_blank" rel="noreferrer noopener">상향 조정한</a> 후 11.30% 상승했다.
6. 부즈 앨런 해밀턴 홀딩(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAH#NYSE">BAH</a>)의 주식은 2분기 재무 실적이 예상보다 좋게 나타나고 <a href="https://www.benzinga.com//node/41543105" target="_blank" rel="noreferrer noopener">2025 회계연도 가이던스가 강하게 나타난</a> 후 10.99% 상승했다.
7. 디지털 리얼티 트러스트(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DLR#NYSE">DLR</a>)의 주식은 3분기 FFO 실적이 예상보다 좋고 2024 회계연도 FFO 가이던스를 상향 조정한 후 9.45% 상승했다. 여러 애널리스트들이 주가 전망을 <a href="https://www.benzinga.com/quote/DLR/analyst-ratings" target="_blank" rel="noreferrer noopener">상향 조정</a>했다.
8. 그랩 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRAB#NASDAQ">GRAB</a>)의 주식은 다이와 캐피털(Daiwa Capital)이 주식을 아웃퍼폼 등급으로 <a href="https://www.benzinga.com/quote/GRAB/analyst-ratings" target="_blank" rel="noreferrer noopener">커버리지 개시하고 $4.60의 목표 주가를 제시</a>한 후 9.12% 상승했다.
9. 마이크로스트레티지(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>)의 주식은 비트코인 가격 상승으로 <a href="https://www.benzinga.com//node/41544385" target="_blank" rel="noreferrer noopener">8.56% 상승</a>했다.
10. 필립 모리스 인터내셔널(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PM#NYSE">PM</a>)의 주식은 회사가 3분기 실적이 예상보다 좋게 나타나고 여러 애널리스트들이 목표 주가를 <a href="https://www.benzinga.com//node/41499153" target="_blank" rel="noreferrer noopener">상향 조정한</a> 후 8.03% 상승했다.
Photo via Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

CPRI

GRAB

MSTR

테슬라와 리 오토는 지난주 최고 성과를 보여준 10개 대형주 중 일부 (10월 21일-10월 25일)

이들 10개 대형주는 지난주 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
1. 니오(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>)의 주식이 지난주 16.35% 하락했다. 이는 미국에 상장된 중국 주식들이 <a href="https://www.benzinga.com//node/41385461" target="_blank" rel="noreferrer noopener">중국의 9월 수출이 예상치를 밑돌면서</a> 하락한 후 발생한 일이다. 중국 경기 부양책에 대한 불확실성도 최근 주식에 악영향을 미쳤다.
2. KLA 코퍼레이션(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLAC#NASDAQ">KLAC</a>)의 주식이 지난주 15.58% 하락했다. 이는 ASML의 부진한 전망 발표 이후 지속적인 약세로 인한 것으로 보인다.
3. 센텐 코퍼레이션(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>)의 주식이 14.38% 하락했다. 이 회사는 <a href="https://www.benzinga.com/earnings" target="_blank" rel="noreferrer noopener">10월 25일 3분기 실적을 발표</a>할 예정이다.
4. 엘레반스 헬스(Elevance Health)의 주식이 14.17% 하락했다. 이는 분석가들이 <a href="https://www.benzinga.com//node/41405601" target="_blank" rel="noreferrer noopener">3분기 실적 발표 후 전망을 하향 조정한</a> 데 따른 것이다.
5. ASML 홀딩 N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASML#NASDAQ">ASML</a>)의 주식이 13.97% 하락했다. 회사가 실적 발표를 하루 일찍 실수로 공개하고 <a href="https://www.benzinga.com//node/41358875" target="_blank" rel="noreferrer noopener">2025년 매출 전망을 하향 조정한</a> 후 발생한 일이다.
6. PDD 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDD#NASDAQ">PDD</a>)의 주식이 13.91% 하락했다. 이는 미국에 상장된 중국 주식들이 <a href="https://www.benzinga.com//node/41316058" target="_blank" rel="noreferrer noopener">중국의 9월 수출이 예상치를 밑돌면서</a> 하락한 것과 함께 발생한 일이다. 중국 경기 부양책에 대한 불확실성도 최근 주식에 악영향을 미쳤다.
7. 몰리나 헬스케어(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>)의 주식이 12.24% 하락했다. 이는 엘레반스 헬스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>)와 동반 하락한 것으로 보인다. 엘레반스 헬스는 3분기 실적 부진과 2024년 전망을 낮춰 발표했다.
8. 램 리서치(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRCX#NASDAQ">LRCX</a>)의 주식이 12.12% 하락했다. 이는 ASML의 부진한 전망 발표 이후 지속적인 약세로 인한 것으로 보인다.
9. 이리 인뎀니티(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ERIE#NASDAQ">ERIE</a>)의 주식이 지난주 9.92% 하락했다. 이는 스프루스 포인트 매니지먼트(Spruce Point Management)가 주식에 대한 <a href="https://www.sprucepointcap.com/research/erie-indemnity-company" target="_blank" rel="noreferrer noopener">공매도 보고서를 발표</a>한 후 발생한 일이다. 이 회사는 카테고리 5 허리케인 밀턴으로 압박을 받았다.
10. CVS 헬스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>)의 주식이 지난 주 9.44% 하락했다. 이 회사가 <a href="https://www.benzinga.com//node/41399396" target="_blank" rel="noreferrer noopener">3분기 전망을 하향 조정</a>한 후 발생한 일이다.
추가 읽기:
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%EC%BD%94%EC%9D%B8%EB%B2%A0%EC%9D%B4%EC%8A%A4%EC%99%80-%EC%9C%A0%EB%82%98%EC%9D%B4%ED%8B%B0%EB%93%9C-%ED%95%AD%EA%B3%B5%EC%9D%80-%EC%A7%80%EB%82%9C%EC%A3%BC-%EC%B5%9C%EA%B3%A0-%EC%84%B1%EA%B3%BC/" target="_blank" rel="noopener">코인베이스, 유나이티드 항공 및 소파이 테크가 지난 주 가장 큰 대형주 상승 종목 중 하나 (10월 14-18일): 다른 종목들은 여러분의 포트폴리오에 포함되어 있나요?</a></li>
</ul>
사진 출처: Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Short Sellers

ASML

KLAC

니오, ASML 및 CVS 헬스는 지난주 최악의 성과를 보인 10개 대형주 중 일부 (10월 14일-18일)

2008년 금융 위기 이전 주택 시장에 대한 선견지명 있는 투자로 유명한 유명 투자자 마이클 버리(Michael Burry)는 2024년 2분기에 자신의 헤지 펀드 포트폴리오에 큰 변화를 주었다.
어떤 일이 (What Happened): 사라토가에 본사를 두고 버리가 운영하는 사이언 에셋 매니지먼트(Scion Asset Management)는 수요일 미국 증권거래위원회(SEC)에 최신 13F 보고서를 제출하여 투자 전략의 주목할만한 변화를 밝혔다.
주요 포인트들은 다음과 같다:
<ol>
<li>알리바바 그룹 홀딩(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>)가 1위 자리를 차지함: 중국의 전자상거래 대기업인 알리바바는 155,000주로 구성된 약 1,116만 달러의 가치를 지닌 사이언의 최대 보유 기업이 되었다.</li>
<li>기술 초점: 이 포트폴리오는 중국 기술 기업들에 대한 지속적인 관심을 보여준다. 이에는 75,000주로 약 649만 달러의 가치를 형성하는 바이두(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>)와 25만 주로 646만 달러의 가치를 형성하는 징동닷컴(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>)의 큰 비중이 포함되어 있다.</li>
<li>헬스케어 및 핀테크: 몰리나 헬스케어(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>)와 시프트4 페이먼츠(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FOUR#NYSE">FOUR</a>)는 각각 729만 달러와 734만 달러 상당의 상당한 투자를 보여준다.</li>
<li>부동산 노출: 허드슨 퍼시픽 프로퍼티즈(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPP#NYSE">HPP</a>)는 550만 달러 상당의 주식 110만 주를 보유한 중요한 부동산 회사로 두각을 나타낸다.</li>
<li>바이오테크 신생기업: 임상 단계의 바이오제약 회사인 바이오아틀라(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCAB#NASDAQ">BCAB</a>)는 포트폴리오에서 작지만 주목할만한 위치를 나타낸다.</li>
</ol>
기타 주목할만한 보유 자산으로는 더 리얼리얼(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REAL#NASDAQ">REAL</a>), 올라플렉스 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OLPX#NASDAQ">OLPX</a>), 그리고 아메리칸 코스탈 인슈어런스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACIC#NASDAQ">ACIC</a>)가 있다.
중요성 (Why It Matters): 이 최신 서류는 버리의 현재 시장 전망에 대한 통찰력을 제공하며 중국 기술 기업, 미국 의료, 핀테크 및 엄선된 부동산 기회에 대한 상당한 투자를 통한 다양한 접근 방식을 제안한다.
지난 5월 버리는 <a href="https://www.benzinga.com/markets/asia/24/05/38878116/big-short-investor-michael-burry-bets-heavy-on-gold-renewable-energy-stocks-exits-amazon-alphabet">금 및 신재생 에너지</a>에 대한 막대한 투자로 헤드라인을 장식했으며 아마존닷컴(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) 및 알파벳(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>)(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>)에서 포지션을 청산했다. 이 전환점은 실물 상품과 지속 가능한 에너지원에 초점을 맞추었음을 나타낸다.
관련해서, <a href="https://www.benzinga.com/general/entertainment/24/07/39695004/elon-musk-warren-buffett-nancy-pelosi-jensen-huang-michael-saylor-who-you-sitting-by-on-a-p">최근의 설문 조사</a>에서는 투자자들이 일론 머스크, 워런 버핏, Burry 자신과 같은 최고 인물들로부터 조언을 구하는 방법을 강조하여 투자 커뮤니티에서 그의 영향력을 강조한다.
Michael Burry illustration by Gonzalo Lanzilotta for
면책 조항: 본 콘텐츠는 인공지능 도구의 도움을 받아 제작되었으며, Benzinga 편집자들에 의해 검토되고 게시되었습니다.
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Asia

AMZN

BCAB

OLPX

REAL

'빅쇼트' 명성의 마이클 버리, 중국에 큰 투자하고 알리바바를 최대 보유 주식으로 공개

Comments

Molina Healthcare

뉴스

에 대한 최신 뉴스 Molina Healthcare (NYSE:MOH) 주식

일요일, 4월 06, 2025

목요일, 2월 27, 2025

수요일, 2월 12, 2025

금요일, 11월 15, 2024

토요일, 10월 26, 2024

일요일, 10월 20, 2024

목요일, 8월 15, 2024

일요일, 7월 28, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌